TAP Pharmaceutical Products Inc.
15
0
0
8
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 50/100
33.3%
5 terminated/withdrawn out of 15 trials
61.5%
-25.0% vs industry average
40%
6 trials in Phase 3/4
100%
8 of 8 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (15)
Growth Hormone and GnRH Agonist in Adolescents With Acquired Hypothyroidism
Role: collaborator
Insulin Resistance and Testosterone in Women
Role: collaborator
A Clinical Trial of Proton Pump Inhibitors to Treat Children With Chronic Otitis Media With Effusion
Role: collaborator
Efficacy of EUS-guided Celiac Plexus Blockade in Chronic Pancreatitis
Role: collaborator
The Study of Barrett's Esophagus: What Are the Factors of Progression
Role: collaborator
Dietary Control Alone Versus Dietary Control Plus Use of Proton Pump Inhibitors to Treat Pediatric Hoarseness
Role: collaborator
Menorrhagia Study in Women With Treatment-resistant Menorrhagia
Role: collaborator
Effect of Prevacid on Prostaglandin Levels in Patient With Stress Ulcer
Role: collaborator
GnRH Analogue for Ovarian Function Preservation in Hematopoietic Stem Cell Transplantation Patients
Role: collaborator
The Frequency of Eosinophilic Esophagitis in Patients With Heartburn That is Refractory to Proton Pump Inhibitors
Role: collaborator
Reflux Disease in Head and Neck Cancer Patients Undergoing Radiation Therapy
Role: collaborator
Efficacy of Lansoprazole in Chronic Post Nasal Drip
Role: collaborator
Importance of Non-Acid Reflux in Asthma in Children
Role: collaborator
Prevacid vs Lifestyle Modifications for the Treatment of LPR
Role: collaborator
Lupron Sex Offender Therapy
Role: collaborator
All 15 trials loaded